CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 113 enrolled
Drug / intervention
GSK Biologicals' investigational vaccine GSK1562902Abiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01323946
NCT01323946Phase 2Completed
CompareCT.gov

Safety and Immunogenicity of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine (GSK1562902A) in Children Aged 6 to 35 Months

GlaxoSmithKline·interventional·Posted Mar 28, 2011·Updated May 7, 2019

In Brief

A Phase 2 clinical trial evaluating GSK Biologicals' investigational vaccine GSK1562902A for Influenza. Completed, enrolled 113 participants across 6 sites in 2 countries.

Detailed Summary

The objective of the study is to evaluate the immunogenicity and safety of prime-boost vaccination schedule of GSK Biologicals' investigational vaccine GSK1562902A.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesAustralia, Singapore
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 28, 2011
Enrollment StartApr 18, 2011
Primary CompletionJun 22, 2012
Study CompletionNov 2, 2012
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 15.3 years ago

Interventions

GSK Biologicals' investigational vaccine GSK1562902Abiological

Three intramuscular injections